Previous 10 | Next 10 |
2023-09-22 15:27:43 ET More on Morphic Seeking Alpha’s Quant Rating on Morphic Historical earnings data for Morphic Financial information for Morphic Morphic: High Valuation Not Justified By Data, Development Status, Or Cash Stifel cuts Morphic...
2023-09-22 12:52:13 ET For further details see: CETX, MYO and MORF among mid-day movers
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Marc Schegerin, MD, COO & CFO, will participate in a...
2023-08-09 18:43:54 ET Stifel has downgraded Morphic ( NASDAQ: MORF ) to hold, stating that it believes open-label data for its anti-inflammatory drug candidate MORF-057 isn't enough to score a near-term M&A deal. Stifel said that while the immunology and inflammation space ...
WALTHAM, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Offic...
2023-08-03 10:36:34 ET Morphic press release ( NASDAQ: MORF ): Q2 GAAP EPS of -$0.92. Revenue was $0 million for the quarter ended June 30, 2023, compared to $60.2 million for the same quarter last year due to the conclusion of the Company’s research and development...
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater than $730 million in cash and equivalents at 6/30/23; extended cash runway into seco...
Morphic Holding, Inc. (NASDAQ: MORF) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.07% on the day to $60.15. Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, c...
2023-07-10 15:12:02 ET Summary Morphic Holding, Inc. is progressing with its trials nicely enough. I just have a problem with the nearly $3bn valuation for this phase 2 stage company. Nothing they have done or said justifies it. Morphic Holding ( MORF ) devel...
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the Jefferies He...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 08:15:05 ET RBC Capital analyst issues SECTOR PERFORM recommendation for MORF on July 9, 2024 06:29AM ET. The previous analyst recommendation was Outperform. MORF was trading at $55.74 at issue of the analyst recommendation. The overall analyst consensus : BUY...
2024-07-08 20:00:07 ET Edward Nash from Canaccord Genuity issued a price target of $57.00 for MORF on 2024-07-08 18:49:00. The adjusted price target was set to $57.00. At the time of the announcement, MORF was trading at $55.74. The overall price target consensus is at $...